01672.HK
Ascletis Pharma Inc.
HKSE · Healthcare · Biotechnology · CN
HKD 4.90
−6.04%Oct 29, 2026, 00:04 UTC
Ascletis Pharma, Inc. announced positive topline results from a U.S. Phase II study of ASC30 for type 2 diabetes, with placebo-adjusted HbA1c reductions at week 12 of 1.7%, 1.6% and 1.7% for the 40 mg, 60 mg and 80 mg groups, respectively.
Source:Oct 26, 2026, 01:34 UTC
Ascletis Pharma, Inc. plans to begin a Phase I trial of oral ASC39 in the fourth quarter of 2026.
Source:Oct 26, 2026, 01:34 UTC
Ascletis Pharma, Inc. submitted an investigational new drug application to the Ascletis Pharma, Inc. for its oral ASC39 tablet.
Source:Oct 26, 2026, 00:20 UTC
Ascletis Pharma, Inc. submitted an investigational new drug application to the U.S. FDA for its oral ASC39 tablet for obesity treatment.
Source:Oct 22, 2026, 11:00 UTC
Sagimet Biosciences Inc. dosed the first patient in AURORA, its U.S. Phase 3 trial of denifanstat for moderate to severe acne.
Oct 20, 2026, 00:09 UTC
Ascletis Pharma, Inc. announced positive preclinical data for its once-weekly oral peptide pipeline for obesity, including ASC36o’s approximately seven-day half-life and 6%–8% oral bioavailability in non-human primates.
Source:Oct 14, 2026, 08:12 UTC
Hong Kong-listed shares showed varied moves, led by gains in Meituan, Xiaomi and Alibaba and declines in several other active constituents; four stocks reached record highs.
Source:Oct 9, 2026, 11:00 UTC
Sagimet announced that positive 52-week results and mechanistic data from Ascletis' Phase 3 ASC40-304 open-label extension trial of denifanstat in acne will be presented at the 2026 Fall Clinical Dermatology Conference.
Source:Oct 6, 2026, 08:12 UTC
Hong Kong stocks closed higher on October 6, 2026, with the Hang Seng Index up 240 points (1.0%) at 24,280, the Hang Seng Tech Index up 39 points (0.9%) at 4,223, and the China Enterprises Index up 77 points (1.0%) at 8,128 on turnover of HK$98.265 billion.
Oct 2, 2026, 08:55 UTC
Ascletis Pharma presented key preclinical data for ASC36_35FDC, a fixed-dose combination of ASC36 and ASC35, at the 62nd EASD Annual Meeting in Milan, Italy, and has developed a once-weekly oral tablet of ASC36_35FDC.
Source:Sep 30, 2026, 10:00 UTC
Sagimet Biosciences announced positive 52-week results from license partner Ascletis BioScience's Phase 3 ASC40-304 open-label extension trial of denifanstat in moderate to severe acne vulgaris, presented at EADV 2026.
Sep 29, 2026, 00:04 UTC
Ascletis Pharma announced positive results from a 28-day proof-of-concept clinical study in the United States of its first-in-class oral small-molecule IL-17A inhibitor ASC50 in patients with mild-to-moderate plaque psoriasis.
Source:Sep 18, 2026, 08:12 UTC
Hong Kong stocks closed higher on September 18, 2026, with the Hang Seng Index up 146 points (0.6%) at 24,750 and the Hang Seng Tech Index up 94 points (2.2%) at 4,405, as Alibaba rose over 3% and Lenovo Group, Liuliumei, Lenovo Holdings, Yingsheng Holdings and GenScript Biotech hit record highs.
Sep 7, 2026, 04:09 UTC
Ascletis Pharma's ordinary shares were included in the eligible securities list of the Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect (collectively 'Stock Connect'), effective from September 7, 2026, allowing eligible mainland Chinese investors to trade the shares.
Source:Sep 4, 2026, 11:33 UTC
Shanghai Stock Exchange announced adjustments to the Stock Connect southbound eligible securities, adding 54 stocks including Baidu and Ascletis Pharma, and removing 15 stocks including Youjia Innovation.
Aug 17, 2026, 08:02 UTC
Sagimet Biosciences plans to begin a Phase III study of denifanstat for moderate-to-severe acne in the U.S. within the next several months, following positive results from a China-based Phase III trial conducted by partner Ascletis.
Source: